Celaidtx
3 known investors
Find your way into Celaidtx
589 people in our graph share verified history with the Celaidtx team — schools, employers, funds. One of them is your warm intro.
Mike Zakunlockedknows Asako Uchiyama · together at Cornell (overlapped)
×8knows the team · via Cornell
knows the team · via Tokyo Institute of Technology
×2knows the team · via Keio University
Celaid Therapeutics develops hematopoietic stem cell expansion technology, including a method to replace albumin with polyvinyl alcohol and to expand human hematopoietic stem cells ex vivo in large quantities. The company applies this technology to stem cell transplantation and gene therapy for blood cancers such as leukemia and other blood and genetic diseases.
Founders & leadership
NA
Nobuyuki ArakawainCo-founder & Representative Director, President & CEONobuyuki Arakawa co-founded Celaid Therapeutics in 2020 and serves as President and CEO; he previously worked as a business consultant on strategy, supply chain, and business development projects across healthcare, electronics, manufacturing, retail, and IT sectors.
MW
Motoo WatanabeinCo-founder / Advisor (former Chairman & CSO)
HN
Hiromitsu NakauchiCo-founder
MS
Masatoshi SakuraiCo-founder
YI
Yusuke InoueinDirector, COO & CFOYusuke Inoue is Director, COO, and CFO at Celaid Therapeutics, a company developing hematopoietic stem cell expansion technology for stem cell transplantation and gene therapy. He previously held finance and operations leadership roles at Takeda Pharmaceuticals in both the United States and Japan, focusing on oncology and GI portfolios.
AU
Asako UchiyamainDirector, CDO (Chief Development Officer)Asako Uchiyama is Director and Chief Development Officer at Celaid Therapeutics, where she leads development of hematopoietic stem cell expansion technology for stem cell transplantation and gene therapy. She brings background in early-phase and preclinical development of gene and cell therapy products, diagnostic method development for infectious diseases, virology research, and international business development.
Investors · 3
Competitors · 6
by search overlap
Cellectis8 shared keywordsCellectis is a biotech company focused on cell therapy and immunotherapy. The company is publicly listed on Nasdaq and Euronext Growth Paris.
Linkcelltx5 shared keywordsLink Cell Therapies is a biotechnology company developing logic-gate LINK CAR-T cell therapies aimed at treating solid and liquid tumors. It works in the cancer immunotherapy space and has a strategic collaboration with Johnson & Johnson.
Kite Pharma4 shared keywordsKite develops CAR T-cell therapies that engineer a patient's own immune cells to target and destroy cancer cells. The company focuses on cell therapy treatments for cancers such as diffuse large B-cell lymphoma.
Celldex Therapeutics, Inc.4 shared keywordsCelldex is a biotechnology company developing therapeutics across therapeutic areas including immunology and inflammation. The page shown is a board director biography rather than a company overview.
Seed Tx4 shared keywordsSEED Therapeutics develops de novo molecular glue degraders for targeted protein degradation, using its RITE3 platform to match E3 ligases with disease-causing target proteins. Its lead RBM39 degrader (ST-01156) is in Phase 1 trials for Ewing sarcoma, hepatocellular carcinoma and related tumors, alongside additional oncology programs.
Cellics Therapeutics3 shared keywordsCellics Therapeutics is a therapeutics company; its website is a placeholder page providing only contact and location details, with no description of its products or focus.
Companies competing with Celaidtx for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Celaidtx do?
- Celaid Therapeutics develops hematopoietic stem cell expansion technology, including a method to replace albumin with polyvinyl alcohol and to expand human hematopoietic stem cells ex vivo in large quantities. The company applies this technology to stem cell transplantation and gene therapy for blood cancers such as leukemia and other blood and genetic diseases.
- Who founded Celaidtx?
- Celaidtx was founded by Nobuyuki Arakawa, Motoo Watanabe, Hiromitsu Nakauchi, Masatoshi Sakurai.
- Who are Celaidtx's investors?
- Celaidtx's investors include Kobe University Capital, OSAKA University Venture Capital, UTEC.